Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer

Takehiko Yokobori, Koshi Mimori, Hideshi Ishii, Masaaki Iwatsuki, Fumiaki Tanaka, Yukio Kamohara, Keisuke Ieta, Yoshiaki Kita, Yuichiro Doki, Hiroyuki Kuwano, Masaki Mori

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated. Materials and Methods: We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2's biological roles. Results: The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05). Conclusions: The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.

Original languageEnglish
Pages (from-to)2601-2607
Number of pages7
JournalAnnals of Surgical Oncology
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 1 2010

Fingerprint

Stomach Neoplasms
teleocalcin
Small Interfering RNA
Endocrine Glands
Gastric Mucosa
Paraffin
Reverse Transcription
Neoplasms
Glycoproteins
Fishes
Mucous Membrane
Lymph Nodes
Cell Proliferation
Databases
Hormones
Neoplasm Metastasis
Cell Line
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. / Yokobori, Takehiko; Mimori, Koshi; Ishii, Hideshi; Iwatsuki, Masaaki; Tanaka, Fumiaki; Kamohara, Yukio; Ieta, Keisuke; Kita, Yoshiaki; Doki, Yuichiro; Kuwano, Hiroyuki; Mori, Masaki.

In: Annals of Surgical Oncology, Vol. 17, No. 10, 01.10.2010, p. 2601-2607.

Research output: Contribution to journalArticle

Yokobori, T, Mimori, K, Ishii, H, Iwatsuki, M, Tanaka, F, Kamohara, Y, Ieta, K, Kita, Y, Doki, Y, Kuwano, H & Mori, M 2010, 'Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer', Annals of Surgical Oncology, vol. 17, no. 10, pp. 2601-2607. https://doi.org/10.1245/s10434-010-1086-0
Yokobori, Takehiko ; Mimori, Koshi ; Ishii, Hideshi ; Iwatsuki, Masaaki ; Tanaka, Fumiaki ; Kamohara, Yukio ; Ieta, Keisuke ; Kita, Yoshiaki ; Doki, Yuichiro ; Kuwano, Hiroyuki ; Mori, Masaki. / Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. In: Annals of Surgical Oncology. 2010 ; Vol. 17, No. 10. pp. 2601-2607.
@article{0ec28906922f42f8a6bed283f24b35ab,
title = "Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer",
abstract = "Background: Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated. Materials and Methods: We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2's biological roles. Results: The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05). Conclusions: The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.",
author = "Takehiko Yokobori and Koshi Mimori and Hideshi Ishii and Masaaki Iwatsuki and Fumiaki Tanaka and Yukio Kamohara and Keisuke Ieta and Yoshiaki Kita and Yuichiro Doki and Hiroyuki Kuwano and Masaki Mori",
year = "2010",
month = "10",
day = "1",
doi = "10.1245/s10434-010-1086-0",
language = "English",
volume = "17",
pages = "2601--2607",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer

AU - Yokobori, Takehiko

AU - Mimori, Koshi

AU - Ishii, Hideshi

AU - Iwatsuki, Masaaki

AU - Tanaka, Fumiaki

AU - Kamohara, Yukio

AU - Ieta, Keisuke

AU - Kita, Yoshiaki

AU - Doki, Yuichiro

AU - Kuwano, Hiroyuki

AU - Mori, Masaki

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated. Materials and Methods: We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2's biological roles. Results: The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05). Conclusions: The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.

AB - Background: Stanniocalcins are glycoprotein hormones that were originally found in the endocrine gland of bony fish. Microarray expression data from 32 paired samples of gastric cancer and normal mucosa in a public microarray database showed that the expression level of Stanniocalcin 2 was higher in gastric cancer than in normal gastric mucosa. The clinical significance of Stanniocalcin 2 expression has been observed for several cancers. However, the relationship between Stanniocalcin 2 and clinicopathological factors in gastric cancer has not yet been investigated. Materials and Methods: We examined the clinical significance of Stanniocalcin 2 in gastric cancer in 108 gastric cancer samples using real-time reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical studies were conducted with paraffin sections. The suppression analysis of Stanniocalcin 2 using siRNA was done to determine Stanniocalcin 2's biological roles. Results: The level of Stanniocalcin 2 in cancer tissues was higher than in normal tissues (P = .0002). The high Stanniocalcin 2 expression group (n = 54) had more progressive lymph node metastasis (P = .07) and venous invasion (P = .028) than the low-expression group (n = 54). High Stanniocalcin 2 expression was an independent prognostic factor in gastric cancer patients (P = .02). Moreover, siRNA suppression of Stanniocalcin 2 in a gastric cancer cell line inhibited cellular proliferation (P < .05). Conclusions: The high expression level of Stanniocalcin 2 in gastric cancer tissues could be a very powerful marker of poor prognosis. Therefore, Stanniocalcin 2 is a promising candidate for a molecular target for the treatment of gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=78049476955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049476955&partnerID=8YFLogxK

U2 - 10.1245/s10434-010-1086-0

DO - 10.1245/s10434-010-1086-0

M3 - Article

C2 - 20422456

AN - SCOPUS:78049476955

VL - 17

SP - 2601

EP - 2607

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -